Prevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act

HIV Medicine

Volumn 15, Issue 8, 2014, Pages 499-504

  Sadlier, C ^a   Rowley, D ^a   Morley, D ^a   Surah, S ^a   O'Dea, S ^a   Delamere, S ^a   O'Leary, J ^a   Smyth, P ^a   Clarke, S ^a   Sheils, O ^a   Bergin, C ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

HIV; HPV; MSM; Prevalence; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN BETA CHAIN; WART VIRUS VACCINE; VIRUS DNA;

ADULT; ANUS; ANUS CANCER; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONSENSUS; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE POLICY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION; SEXUAL BEHAVIOR; VACCINATION; VIRUS DETECTION; VIRUS STRAIN; WART VIRUS; WILCOXON SIGNED RANKS TEST; ANAL CANAL; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MALE HOMOSEXUALITY; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; VIROLOGY;

ADULT; ANAL CANAL; COHORT STUDIES; DNA, VIRAL; GENOTYPE; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDIES;

EID: 84906310494     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12150     Document Type: Article

References (27)

1. Dunne EF, Unger ER, Sternberg M etal. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-819.
2. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.
3. Jemal A, Simard EP, Dorell C etal. Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. J Natl Cancer Inst 2013; 105: 175-201.
4. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24: S11-S25.
5. Patel P etal. 'Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736.
6. D'Souza G, Wiley DJ, Li X etal. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 491-499.
7. Daling JR, Madeleine MM, Johnson LG etal. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-280.
8. Silverberg MJ, Lau B, Justice AC etal. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 1026-1034.
9. Ryan M. An evaluation of the impact of highly active antiretroviral therapy on the pharmacoeconomics and pharmacoepidemiology of HIV infection. PhD thesis accepted 2001. University of Dublin, Trinity College.
10. Palella FJ Jr, Baker RK, Moorman AC etal. ; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
11. Brown DR, Kjaer SK, Sigurdsson K etal. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199: 926-935.
12. De Carvalho N, Teixeira J, Roteli-Martins CM etal. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7·3 years in young adult women. Vaccine 2010; 28: 6247-6255.
13. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
14. Paavonen J, Naud P, Salmeron J etal. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
15. Giuliano AR etal. 'Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364: 401-411.
16. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884.
17. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10: 845-852.
18. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012; 54: 891-898.
19. Sahasrabuddhe VV, Castle PE, Follansbee S etal. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis 2013; 207: 392-401.
20. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 2375-2383.
21. Sirera G, Videla S, Pinol M etal. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. Aids 2006; 20: 1201-1204.
22. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177: 361-367.
23. Nyitray AG, Carvalho da Silva RJ, Baggio ML etal. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis 2011; 204: 1711-1722.
24. Poynten I, Fengyi J, Templeton D etal. Prevalence, incidence, and risk factors for Human Papillomavirus 16 seropositivity in Australian homosexual men. Sex Transm Dis 2012; 39: 726-732.
25. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 2004; 31: 601-607.
26. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005; 14: 1528-1533.
27. Rock C, de Barra E, Sadlier C etal. Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health 2013; 6: 173-178.